Contipro Pharma a.s.   Report issue

For profit Phase 2
Founded: Dolní Dobrouč Czech Republic (1990)
Status: No NME R&D (1990)

Organization Overview

First Clinical Trial
2015
NCT04091399
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Contipro Pharma a.s.

Active Ingredients

Drugs in Phase 2 Trials (2)

hyaluronic acid (1 trial)

octenidine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Socket (Phase 2)

Osteitis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2